C12N 2501/505
Cd4
Official title: Cd4; cd8
C12N2501/505 (Cd4) appears on 53 US grants and 135 published applications in this corpus.
Search patents in C12N- Granted patents
- 53
- Published applications
- 135
- Assignees
- 97
- Inventors
- 322
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 2 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 3 |
| 2015 | 2 | 3 |
| 2016 | 2 | 0 |
| 2017 | 0 | 7 |
| 2018 | 2 | 7 |
| 2019 | 3 | 13 |
| 2020 | 1 | 10 |
| 2021 | 5 | 15 |
| 2022 | 6 | 15 |
| 2023 | 6 | 15 |
| 2024 | 5 | 13 |
| 2025 | 4 | 16 |
| 2026 | 10 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of manufacturing CAR-T cells1 Sep 2026US 12,723,268 B2Crispr Therapeutics AG
- Hematopoietic progenitor cell marker11 Aug 2026US 12,703,852 B2Kyoto University
- Identifying epigenetic and transcriptional targets to prevent and reverse T cell exhaustion4 Aug 2026US 12,698,499 B2The Trustees of the University of Pennsylvania
- Genomic engineering of pluripotent cells2 Jun 2026US 12,642,852 B1Fate Therapeutics, Inc.
- Manipulation and use of antigen-specific regulatory T cells26 May 2026US 12,636,317 B2The Board of Trustees of the Leland Stanford Junior University
- Chimeric cd8-alpha co-receptor compositions and methods of use20 Aug 2026US 2026/0242442 A1Poseida Therapeutics, Inc.
- Cd4 + and cd8 + single positive t cells and compositions and methods for generating the same20 Aug 2026US 2026/0242728 A1Clade Therpaeutics, Inc.
- T cell production method23 Apr 2026US 2026/0109949 A1Kyoto University
- Compositions comprising regulatory t cells and methods of making and using the same12 Feb 2026US 2026/0041688 A1Cellenkos, Inc.
- Cell therapies for multiple sclerosis5 Feb 2026US 2026/0034215 A1Abata Therapeutics, Inc.
Most cited
By later US patents
- Genomic engineering of pluripotent cells25US 10,287,606 B2Fate Therapeutics, Inc. · 2019
- Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof15US 10,273,280 B2iCell Gene Therapeutics Inc. · 2019
- Genomic engineering of pluripotent cells15US 11,072,781 B2Fate Therapeutics, Inc. · 2021
- Cell10US 10,098,926 B2Autolus Limited · 2018
- M971 chimeric antigen receptors6US 10,072,078 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2018